Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer

Abstract

This study expands our knowledge on MIBC not responding to cisplatin by suggesting molecular subtypes to understand the biology of these tumors. Although these molecular subtypes imply consequences for adjuvant treatments, this ultimately needs to be tested in clinical trials.